Using data scraping techniques to gather data from a variety of previously disjointed sources—some proprietary and some publicly available—this research applies the analytical techniques of data visualization and machine learning to (1) gain exploratory insights into the drivers of prescription drug list prices and (2) test how well these variables impact prices directly and interact to predict pricing. Specifically, this inductive analysis considers characteristics related to the brand (i.e., manufacturer, brand/generic classification), product attributes (i.e., dosing levels, amount of active ingredient), the condition for which the drug is recommended (i.e., therapeutic class, subclass, and pricing tier), and market factors (i.e., number of drugs in class and approval year). Through these analytic analyses, the authors seek to cut through some of the opacity of pharmaceutical drug list prices to consider the drivers of drug prices, evaluate how these insights might drive marketplace and policy solutions, and spark future research inquiries in this area.
American Medical Association (2019), How are Prescription Drug Prices Determined?Chicago: American Medical Association.
2.
BerchickEdward R.HoodEmilyBarnettJessica C. (2018), Health Insurance Coverage in the United States: 2017. Washington, D.C.: U.S. Government Printing Office, 60–64.
3.
BerndtErnst R.MortimerRichardBhattacharjyaAshokePareceAndrewTuttleEdward (2007), “Authorized Generic Drugs, Price Competition, and Consumers’ Welfare,” Health Affairs, 26 (3), 790–99.
4.
CapellaMichael L.TaylorCharles R.CampbellRandall C.LongwellLance S. (2009), “Do Pharmaceutical Marketing Activities Raise Prices? Evidence from Five Major Therapeutic Classes,” Journal of Public Policy & Marketing, 28 (2), 146–61.
CurtissFredericLettrichPhillipFairmanKathleen (2010), “What Is the Price Benchmark to Replace Average Wholesale Price (AWP)?” Journal of Managed Care Pharmacy, 16 (7), 492–501.
7.
DanzonPatricia M.TaylorErin (2009), “Drug Pricing and Value in Oncology,” The Oncologist, 15 (1), 24–31.
8.
Department of Health and Human Services (2016), “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees,” 84 FR 2340, 2340–63.
9.
Department of Health and Human Services (2018a), “American Patients First: Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,” 83 FR 22692, 22692–700.
10.
Department of Health and Human Services (2018b), “Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency,” 84 FR 20732, 20732–758.
DiMasiJoseph A. (2000), “New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms,” Drug Information Journal, 34 (4), 1169–94.
13.
EichlerHans-GeorgHurtsHugoBroichKarlRasiGuido (2016), “Drug Regulation and Pricing—Can Regulators Influence Affordability?” The New England Journal of Medicine, 374 (19), 1807–09.
FeldmanRobin (2019), “The Perils of Value-Based Pricing for Prescription Drugs,” The Washington Post (April 11), https://www.washingtonpost.com/outlook/2019/04/11/perils-value-based-pricing-prescription-drugs/.
FrankRichard G.SalkeverDavid S., (1997), “Generic Entry and the Pricing of Pharmaceuticals,” Journal of Economics and Management Strategy, 6 (1), 75–90.
18.
FrazierKenneth C. (2020), “Affording Medicines for Today’s Patients and Sustaining Innovation for Tomorrow,”Journal of the American Medical Association, 323 (9), 831–33.
19.
GencarelliDawn M. (2005), “One Pill, Many Prices: Variation in Prescription Drug Prices in Selected Government Programs,” National Health Policy Forum, 807, 1–20.
20.
GiaccottoCarmelloSanterreRexford E.VernonJohn A. (2005), “Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry,” The Journal of Law and Economics, 48 (1), 195–214.
21.
Government Accountability Office (2009), Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases. Washington, D.C.: United States Government Accountability Office.
22.
GrennanMatthew (2013), “Price Discrimination and Bargaining: Empirical Evidence from Medical Devices,” American Economic Review, 103 (1), 145–77.
23.
HastieTrevor. J.TibshiraniRobert. J.FriedmanJerome H. (2009), The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd ed. New York: Springer-Verlag.
24.
IacoccaKathleenMaharStephen (2019), “Cooperative Partnerships and Pricing in the Pharmaceutical Supply Chain,” International Journal of Production Research, 57 (6), 1724–40.
25.
IacoccaKathleenSawhillJamesZhaoYao (2013), “A Multiple Regression Model to Explain the Cost of Brand-Drugs,” Socio-Economic Planning Sciences, 47 (3), 238–46.
26.
IacoccaKathleenSawhillJamesZhaoYao (2015), “Why Brand Drugs Priced Higher than Generic Equivalents,” International Journal of Pharmaceutical and Healthcare Marketing, 9 (1), 3–19.
27.
JenaAnupam B.CalfeeJohn E.MansleyEdward C.PhilipsonTomas J. (2009), “‘Me-Too’ Innovation in Pharmaceutical Markets,” Forum for Health Economics & Policy, 12 (1), 5.
28.
JönnsonBjörn (2001), “Flat or Monotonic Pricing of Pharmaceuticals: Practice and Consequences,” Health Economics in Prevention and Care, 2 (3), 104–12.
29.
KaastraIebelingBoydMilton (1996), “Designing a Neural Network for Forecasting Financial and Economic Time Series,” Neurocomputing, 10 (3), 215–36.
KesllerDavid A.RoseJanet L.TempleRobert J.SchapiroRenieGriffinJoseph P. (1994), “Therapeutic-Class Wars: Drug Promotion in a Competitive Marketplace,” The New England Journal of Medicine, 331 (20), 1350–53.
34.
KesselheimAaron S.AvornJerrySarpatwariAmeet (2016), “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” Journal of the American Medical Association, 316 (8), 858–71.
LaValleSteveLesserEricShockleyRebeccaHopkinsMichael S.KruschwitzNina (2011), “Big Data, Analytics, and the Path from Insights to Value,” MIT Sloan Management Review, 52 (2), 21–32.
LuZ. JohnComanorWilliam S. (1998), “Strategic Pricing of New Pharmaceuticals,” The Review of Economics and Statistics, 80 (1), 108–18.
40.
MahoneyAnneEvansJonathan (2008). “Comparing Drug Classification Systems,” AMIA Symposium Proceedings, 1039.
41.
MoonSuerieMariatStephanieKamaeIsaoPedersenHanne Bak (2020), “Defining the Concept of Fair Pricing for Medicines,” British Medical Journal, 368, 14726.
42.
MossGilesSchuilingIsabelle (2004), “A Brand Logic for Pharma? A Possible Strategy Based on FMCG Experience,” Journal of Medical Marketing, 4 (1), 55–62.
43.
PaulyMark V. (2017), “The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems,” Value in Health, 20 (2), 278–82.
RiversPatrick A.HallNina GermanFrimpongJemima (2006), “Prescription Drug Spending: Contribution to Health Care Spending and Cost Containment Strategies,” Journal of Health Care Finance, 32 (3), 8–19.
SarkarManishLeongTze-Yun (2000), “Application of K-Nearest Neighbors Algorithm on Breast Cancer Diagnosis Problem,” AMIA Symposium Proceedings, 2000, 759–63.
49.
SchuilingIsabelleMossGiles (2004), “How Different are Branding Strategies in the Pharmaceutical Industry and the Fast-Moving Consumer Goods Sector?” Journal of Brand Management, 11 (5), 366–80.
50.
SchwartzLisa M.WoloshinSteven (2019), “Medical Marketing in the United States, 1997–2016,” Journal of the American Medical Association, 321 (1), 80–96.
51.
SheeHassanCheruiyotKiprutoKimaniStephen (2014), “Application of k-Nearest Neighbour Classification in Medical Data Mining,” International Journal of Information and Communication Technology Research, 4 (4), 121–28.
52.
ShmueliGalitBrucePeterPatelNitin (2016), Data Mining for Business Analytics: Concepts, Techniques, and Applications in Microsoft Office Excel with XLminer. New York: Wiley.
WineingerNathan E.YunyueZhangTopalEric J. (2019), “Trends in Prices of Popular Brand-Name Prescription Drugs in the United States,” Journal of the American Medical Association Open Network, 2 (5), e194791.
